Review



igd fitc  (SouthernBiotech)


Bioz Verified Symbol SouthernBiotech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    SouthernBiotech igd fitc
    Igd Fitc, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 93/100, based on 54 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+igd/Goat+Anti-Human+IgD-FITC/pm41820674-308-17-23
    Average 93 stars, based on 54 article reviews
    igd fitc - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    Bioprocessing:

    Article Title: Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistence
    Article Snippet: .. Combinations of fluorochrome-conjugated monoclonal antibodies used for staining included anti-CD3 (SP34-2: BUV395; BD Biosciences, Custom Bulk 624310 and APC-Cy7; BD Biosciences, Custom Bulk 624072), anti-CD4 (L200: BV786; BD Biosciences, Custom Bulk 624159 and BV510; BD Biosciences, Custom Bulk 624340), anti-CD8α (DK25: Pacific Blue; SK1: BUV737; BD Biosciences, Custom Bulk 624235, BV711; BD Biosciences, Custom Bulk 624148 and BV510; BD Biosciences, Custom Bulk 624144), anti-CD95 (DX2: PE; BioLegend, Custom Bulk 94203 and APC; ebioscience, Custom Bulk 7017-0959-M050 and BUV737; BD Biosciences, Custom Bulk 624231), anti-CD28 (CD28.2: PE-DAZZ; BioLegend, Custom Bulk 93364), anti-CCR5 (3A9: APC; BD Biosciences, Custom Bulk 624076), anti-Ki67 (B56: FITC; BD Biosciences, Custom Bulk 624046 and PE; BD Biosciences, Custom Bulk 624048), anti-CD14 (M5E2: FITC; BioLegend, Custom Bulk 94202), anti-CD16 (3G8: BV650; BD Biosciences, Custom Bulk 93384), anti-HLA-DR (L243: PE-DAZZ; BioLegend, Custom Bulk 93957 and BV510; BioLegend, Custom Bulk 93784), anti-CD20 (2H7: APC-Cy7; BioLegend, Custom Bulk 93924), anti-CCR7 (150503: Biotin; R&D Systems, MAB197 and BV711, BD Biosciences, Custom Bulk 624386), anti-NKG2A (REA110: APC; Miltenyi, 130-095-212 and PE, Miltenyi, 130-095-212), anti-CD56 (MEM-188: PerCP-Cy5.5, Life Technologies, MHCD5618CS3), anti-CD69 (CH/4: PerCP-Cy5.5; Life Technologies, MHCD6918), anti-CD27 (M-T271: BV421; BioLegend, Custom Bulk 86409), anti-CD21 (B-ly4: BV711; BD Biosciences, Custom Bulk 624148), anti-IgD (PE; Southern Biotech, 2030–09), anti-PD-1 (eBioJ105: PerCP-Cy5.5; Life Technologies, Custom Bulk CUST00656), anti-CXCR3 (G025H7: BV510; BioLegend, Custom Bulk 94271), anti-CXCR5 (MU5UBEE: PE; Life Technologies, Custom Bulk CUST03534) anti-CD169 (7–239: PE; BioLegend, Custom Bulk 346004) anti-CD123 (7G3: PerCP-Cy5.5; BD Biosciences, Custom Bulk 624060), anti-CD11c (3.9: APC; Life Technologies, Custom Bulk CUST01764), anti-CD86 (2331 [FUN-1]: BV711; BD Biosciences, Custom Bulk 624316), anti-CD40 (5C3: BV510; BD Biosciences, Custom Bulk 624146), anti-CD80 (L307.4: BUV; BD Biosciences, Custom Bulk 624309), anti-CD127 (HIL-7R-M21: BV605; BD Biosciences, Custom Bulk 624143) and anti-streptavidin (BV421; BD Biosciences, Custom Bulk 624337 and BV605, BD Biosciences Custom Bulk 624342). ..

    Article Title: Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistence.
    Article Snippet: .. Combinations of fluorochrome-conjugated monoclonal antibodies used for staining included anti-CD3 (SP34-2: BUV395; BD Biosciences, Custom Bulk 624310 and APC-Cy7; BD Biosciences, Custom Bulk 624072), anti-CD4 (L200: BV786; BD Biosciences, Custom Bulk 624159 and BV510; BD Biosciences, Custom Bulk 624340), anti-CD8α (DK25: Pacific Blue; SK1: BUV737; BD Biosciences, Custom Bulk 624235, BV711; BD Biosciences, Custom Bulk 624148 and BV510; BD Biosciences, Custom Bulk 624144), anti-CD95 (DX2: PE; BioLegend, Custom Bulk 94203 and APC; ebioscience, Custom Bulk 7017-0959-M050 and BUV737; BD Biosciences, Custom Bulk 624231), anti-CD28 (CD28.2: PE-DAZZ; BioLegend, Custom Bulk 93364), anti-CCR5 (3A9: APC; BD Biosciences, Custom Bulk 624076), anti-Ki67 (B56: FITC; BD Biosciences, Custom Bulk 624046 and PE; BD Biosciences, Custom Bulk 624048), anti- PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1012496 August 22, 2024 19 / 28 CD14 (M5E2: FITC; BioLegend, Custom Bulk 94202), anti-CD16 (3G8: BV650; BD Biosciences, Custom Bulk 93384), anti-HLA-DR (L243: PE-DAZZ; BioLegend, Custom Bulk 93957 and BV510; BioLegend, Custom Bulk 93784), anti-CD20 (2H7: APC-Cy7; BioLegend, Custom Bulk 93924), anti-CCR7 (150503: Biotin; R&D Systems, MAB197 and BV711, BD Biosciences, Custom Bulk 624386), anti-NKG2A (REA110: APC; Miltenyi, 130-095-212 and PE, Miltenyi, 130-095-212), anti-CD56 (MEM-188: PerCP-Cy5.5, Life Technologies, MHCD5618CS3), antiCD69 (CH/4: PerCP-Cy5.5; Life Technologies, MHCD6918), anti-CD27 (M-T271: BV421; BioLegend, Custom Bulk 86409), anti-CD21 (B-ly4: BV711; BD Biosciences, Custom Bulk 624148), anti-IgD (PE; Southern Biotech, 2030–09), anti-PD-1 (eBioJ105: PerCP-Cy5.5; Life Technologies, Custom Bulk CUST00656), anti-CXCR3 (G025H7: BV510; BioLegend, Custom Bulk 94271), anti-CXCR5 (MU5UBEE: PE; Life Technologies, Custom Bulk CUST03534) anti-CD169 (7–239: PE; BioLegend, Custom Bulk 346004) anti-CD123 (7G3: PerCP-Cy5.5; BD Biosciences, Custom Bulk 624060), anti-CD11c (3.9: APC; Life Technologies, Custom Bulk CUST01764), anti-CD86 (2331 [FUN-1]: BV711; BD Biosciences, Custom Bulk 624316), anti-CD40 (5C3: BV510; BD Biosciences, Custom Bulk 624146), anti-CD80 (L307.4: BUV; BD Biosciences, Custom Bulk 624309), anti-CD127 (HIL-7R-M21: BV605; BD Biosciences, Custom Bulk 624143) and anti-streptavidin (BV421; BD Biosciences, Custom Bulk 624337 and BV605, BD Biosciences Custom Bulk 624342). ..

    Staining:

    Article Title: Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistence
    Article Snippet: .. Combinations of fluorochrome-conjugated monoclonal antibodies used for staining included anti-CD3 (SP34-2: BUV395; BD Biosciences, Custom Bulk 624310 and APC-Cy7; BD Biosciences, Custom Bulk 624072), anti-CD4 (L200: BV786; BD Biosciences, Custom Bulk 624159 and BV510; BD Biosciences, Custom Bulk 624340), anti-CD8α (DK25: Pacific Blue; SK1: BUV737; BD Biosciences, Custom Bulk 624235, BV711; BD Biosciences, Custom Bulk 624148 and BV510; BD Biosciences, Custom Bulk 624144), anti-CD95 (DX2: PE; BioLegend, Custom Bulk 94203 and APC; ebioscience, Custom Bulk 7017-0959-M050 and BUV737; BD Biosciences, Custom Bulk 624231), anti-CD28 (CD28.2: PE-DAZZ; BioLegend, Custom Bulk 93364), anti-CCR5 (3A9: APC; BD Biosciences, Custom Bulk 624076), anti-Ki67 (B56: FITC; BD Biosciences, Custom Bulk 624046 and PE; BD Biosciences, Custom Bulk 624048), anti-CD14 (M5E2: FITC; BioLegend, Custom Bulk 94202), anti-CD16 (3G8: BV650; BD Biosciences, Custom Bulk 93384), anti-HLA-DR (L243: PE-DAZZ; BioLegend, Custom Bulk 93957 and BV510; BioLegend, Custom Bulk 93784), anti-CD20 (2H7: APC-Cy7; BioLegend, Custom Bulk 93924), anti-CCR7 (150503: Biotin; R&D Systems, MAB197 and BV711, BD Biosciences, Custom Bulk 624386), anti-NKG2A (REA110: APC; Miltenyi, 130-095-212 and PE, Miltenyi, 130-095-212), anti-CD56 (MEM-188: PerCP-Cy5.5, Life Technologies, MHCD5618CS3), anti-CD69 (CH/4: PerCP-Cy5.5; Life Technologies, MHCD6918), anti-CD27 (M-T271: BV421; BioLegend, Custom Bulk 86409), anti-CD21 (B-ly4: BV711; BD Biosciences, Custom Bulk 624148), anti-IgD (PE; Southern Biotech, 2030–09), anti-PD-1 (eBioJ105: PerCP-Cy5.5; Life Technologies, Custom Bulk CUST00656), anti-CXCR3 (G025H7: BV510; BioLegend, Custom Bulk 94271), anti-CXCR5 (MU5UBEE: PE; Life Technologies, Custom Bulk CUST03534) anti-CD169 (7–239: PE; BioLegend, Custom Bulk 346004) anti-CD123 (7G3: PerCP-Cy5.5; BD Biosciences, Custom Bulk 624060), anti-CD11c (3.9: APC; Life Technologies, Custom Bulk CUST01764), anti-CD86 (2331 [FUN-1]: BV711; BD Biosciences, Custom Bulk 624316), anti-CD40 (5C3: BV510; BD Biosciences, Custom Bulk 624146), anti-CD80 (L307.4: BUV; BD Biosciences, Custom Bulk 624309), anti-CD127 (HIL-7R-M21: BV605; BD Biosciences, Custom Bulk 624143) and anti-streptavidin (BV421; BD Biosciences, Custom Bulk 624337 and BV605, BD Biosciences Custom Bulk 624342). ..

    Article Title: Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistence.
    Article Snippet: .. Combinations of fluorochrome-conjugated monoclonal antibodies used for staining included anti-CD3 (SP34-2: BUV395; BD Biosciences, Custom Bulk 624310 and APC-Cy7; BD Biosciences, Custom Bulk 624072), anti-CD4 (L200: BV786; BD Biosciences, Custom Bulk 624159 and BV510; BD Biosciences, Custom Bulk 624340), anti-CD8α (DK25: Pacific Blue; SK1: BUV737; BD Biosciences, Custom Bulk 624235, BV711; BD Biosciences, Custom Bulk 624148 and BV510; BD Biosciences, Custom Bulk 624144), anti-CD95 (DX2: PE; BioLegend, Custom Bulk 94203 and APC; ebioscience, Custom Bulk 7017-0959-M050 and BUV737; BD Biosciences, Custom Bulk 624231), anti-CD28 (CD28.2: PE-DAZZ; BioLegend, Custom Bulk 93364), anti-CCR5 (3A9: APC; BD Biosciences, Custom Bulk 624076), anti-Ki67 (B56: FITC; BD Biosciences, Custom Bulk 624046 and PE; BD Biosciences, Custom Bulk 624048), anti- PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1012496 August 22, 2024 19 / 28 CD14 (M5E2: FITC; BioLegend, Custom Bulk 94202), anti-CD16 (3G8: BV650; BD Biosciences, Custom Bulk 93384), anti-HLA-DR (L243: PE-DAZZ; BioLegend, Custom Bulk 93957 and BV510; BioLegend, Custom Bulk 93784), anti-CD20 (2H7: APC-Cy7; BioLegend, Custom Bulk 93924), anti-CCR7 (150503: Biotin; R&D Systems, MAB197 and BV711, BD Biosciences, Custom Bulk 624386), anti-NKG2A (REA110: APC; Miltenyi, 130-095-212 and PE, Miltenyi, 130-095-212), anti-CD56 (MEM-188: PerCP-Cy5.5, Life Technologies, MHCD5618CS3), antiCD69 (CH/4: PerCP-Cy5.5; Life Technologies, MHCD6918), anti-CD27 (M-T271: BV421; BioLegend, Custom Bulk 86409), anti-CD21 (B-ly4: BV711; BD Biosciences, Custom Bulk 624148), anti-IgD (PE; Southern Biotech, 2030–09), anti-PD-1 (eBioJ105: PerCP-Cy5.5; Life Technologies, Custom Bulk CUST00656), anti-CXCR3 (G025H7: BV510; BioLegend, Custom Bulk 94271), anti-CXCR5 (MU5UBEE: PE; Life Technologies, Custom Bulk CUST03534) anti-CD169 (7–239: PE; BioLegend, Custom Bulk 346004) anti-CD123 (7G3: PerCP-Cy5.5; BD Biosciences, Custom Bulk 624060), anti-CD11c (3.9: APC; Life Technologies, Custom Bulk CUST01764), anti-CD86 (2331 [FUN-1]: BV711; BD Biosciences, Custom Bulk 624316), anti-CD40 (5C3: BV510; BD Biosciences, Custom Bulk 624146), anti-CD80 (L307.4: BUV; BD Biosciences, Custom Bulk 624309), anti-CD127 (HIL-7R-M21: BV605; BD Biosciences, Custom Bulk 624143) and anti-streptavidin (BV421; BD Biosciences, Custom Bulk 624337 and BV605, BD Biosciences Custom Bulk 624342). ..

    Blocking Assay:

    Article Title: Multifaceted effects of soluble human CD6 in experimental cancer models
    Article Snippet: The plasma levels of shCD6 and smCD6 were quantified with the human soluble CD6 PicoKine ELISA Kit (Boster Bio) and the DuoSet mouse CD6 kit (R&D Systems), respectively, following manufacturer’s instructions. .. Surface stainings were performed by blocking cells in phosphate-buffered saline (PBS) plus 10% FBS for 30 min at 4°C with rat anti-mouse CD16/32 (2.4G2; Mouse BD Fc Block) and further incubation with the following labeled mAb and appropriate isotype controls: biotin-labeled anti-BP-1 (6C3, eBioscience); fluorescein isothiocyanate (FITC)-labeled anti-CD4 (RM4-5, Tonbo Biosciences), anti-B220 (Ra3-6B2, Tonbo), anti-CD44 (IM7, BD Biosciences), and anti-CD24 (M1/69, BD Pharmingen); phycoerythrin-labeled anti-IgD (11-26, SouthernBiotech), anti-NK1.1 (PK136, BD Biosciences), anti-CD8 (53-6.7, BioLegend), anti-FoxP3 (3G3, Tonbo), anti-CD19 (1D3, Tonbo), and anti-ALCAM (eBioALC48, eBiosciences); PerCP-Cy5.5-labeled anti-CD3 (145-2 C11, Tonbo), anti-CD8 (53-6.7, Tonbo), anti-CD44 (IM7, Tonbo), and streptavidin (BD Biosciences); allophycocyanin-labeled anti-CD3 (145-2 C11, Tonbo), anti-CD62L (MEL-14, Tonbo), anti-CD3ε (145-2 C11, Tonbo), anti-IgM (II/41, eBioscience), anti-LAP (TW7-16B4, Biolegend), and anti-CD25 (PC61.5, eBiosciences); APC-Cy7-labeled anti-CD25 (PC61, BD Pharmingen); Pe-Cy7-labeled anti-CD5 (53–7.3, eBiosciences), anti-CD19 (1D3, Tonbo), and anti-CD4 (GK1.5, BioLegend); violetFluor 450-labeled anti-B220 (RA3-6B2, Tonbo) and anti-CD8 (53-6.7, Tonbo). .. FoxP3 intracellular staining was performed with the phycoerythrin-labeled anti-mouse/rat Treg Staining Kit (eBioscience), according to the manufacturer’s instructions.

    Saline:

    Article Title: Multifaceted effects of soluble human CD6 in experimental cancer models
    Article Snippet: The plasma levels of shCD6 and smCD6 were quantified with the human soluble CD6 PicoKine ELISA Kit (Boster Bio) and the DuoSet mouse CD6 kit (R&D Systems), respectively, following manufacturer’s instructions. .. Surface stainings were performed by blocking cells in phosphate-buffered saline (PBS) plus 10% FBS for 30 min at 4°C with rat anti-mouse CD16/32 (2.4G2; Mouse BD Fc Block) and further incubation with the following labeled mAb and appropriate isotype controls: biotin-labeled anti-BP-1 (6C3, eBioscience); fluorescein isothiocyanate (FITC)-labeled anti-CD4 (RM4-5, Tonbo Biosciences), anti-B220 (Ra3-6B2, Tonbo), anti-CD44 (IM7, BD Biosciences), and anti-CD24 (M1/69, BD Pharmingen); phycoerythrin-labeled anti-IgD (11-26, SouthernBiotech), anti-NK1.1 (PK136, BD Biosciences), anti-CD8 (53-6.7, BioLegend), anti-FoxP3 (3G3, Tonbo), anti-CD19 (1D3, Tonbo), and anti-ALCAM (eBioALC48, eBiosciences); PerCP-Cy5.5-labeled anti-CD3 (145-2 C11, Tonbo), anti-CD8 (53-6.7, Tonbo), anti-CD44 (IM7, Tonbo), and streptavidin (BD Biosciences); allophycocyanin-labeled anti-CD3 (145-2 C11, Tonbo), anti-CD62L (MEL-14, Tonbo), anti-CD3ε (145-2 C11, Tonbo), anti-IgM (II/41, eBioscience), anti-LAP (TW7-16B4, Biolegend), and anti-CD25 (PC61.5, eBiosciences); APC-Cy7-labeled anti-CD25 (PC61, BD Pharmingen); Pe-Cy7-labeled anti-CD5 (53–7.3, eBiosciences), anti-CD19 (1D3, Tonbo), and anti-CD4 (GK1.5, BioLegend); violetFluor 450-labeled anti-B220 (RA3-6B2, Tonbo) and anti-CD8 (53-6.7, Tonbo). .. FoxP3 intracellular staining was performed with the phycoerythrin-labeled anti-mouse/rat Treg Staining Kit (eBioscience), according to the manufacturer’s instructions.

    Incubation:

    Article Title: Multifaceted effects of soluble human CD6 in experimental cancer models
    Article Snippet: The plasma levels of shCD6 and smCD6 were quantified with the human soluble CD6 PicoKine ELISA Kit (Boster Bio) and the DuoSet mouse CD6 kit (R&D Systems), respectively, following manufacturer’s instructions. .. Surface stainings were performed by blocking cells in phosphate-buffered saline (PBS) plus 10% FBS for 30 min at 4°C with rat anti-mouse CD16/32 (2.4G2; Mouse BD Fc Block) and further incubation with the following labeled mAb and appropriate isotype controls: biotin-labeled anti-BP-1 (6C3, eBioscience); fluorescein isothiocyanate (FITC)-labeled anti-CD4 (RM4-5, Tonbo Biosciences), anti-B220 (Ra3-6B2, Tonbo), anti-CD44 (IM7, BD Biosciences), and anti-CD24 (M1/69, BD Pharmingen); phycoerythrin-labeled anti-IgD (11-26, SouthernBiotech), anti-NK1.1 (PK136, BD Biosciences), anti-CD8 (53-6.7, BioLegend), anti-FoxP3 (3G3, Tonbo), anti-CD19 (1D3, Tonbo), and anti-ALCAM (eBioALC48, eBiosciences); PerCP-Cy5.5-labeled anti-CD3 (145-2 C11, Tonbo), anti-CD8 (53-6.7, Tonbo), anti-CD44 (IM7, Tonbo), and streptavidin (BD Biosciences); allophycocyanin-labeled anti-CD3 (145-2 C11, Tonbo), anti-CD62L (MEL-14, Tonbo), anti-CD3ε (145-2 C11, Tonbo), anti-IgM (II/41, eBioscience), anti-LAP (TW7-16B4, Biolegend), and anti-CD25 (PC61.5, eBiosciences); APC-Cy7-labeled anti-CD25 (PC61, BD Pharmingen); Pe-Cy7-labeled anti-CD5 (53–7.3, eBiosciences), anti-CD19 (1D3, Tonbo), and anti-CD4 (GK1.5, BioLegend); violetFluor 450-labeled anti-B220 (RA3-6B2, Tonbo) and anti-CD8 (53-6.7, Tonbo). .. FoxP3 intracellular staining was performed with the phycoerythrin-labeled anti-mouse/rat Treg Staining Kit (eBioscience), according to the manufacturer’s instructions.

    Labeling:

    Article Title: Multifaceted effects of soluble human CD6 in experimental cancer models
    Article Snippet: The plasma levels of shCD6 and smCD6 were quantified with the human soluble CD6 PicoKine ELISA Kit (Boster Bio) and the DuoSet mouse CD6 kit (R&D Systems), respectively, following manufacturer’s instructions. .. Surface stainings were performed by blocking cells in phosphate-buffered saline (PBS) plus 10% FBS for 30 min at 4°C with rat anti-mouse CD16/32 (2.4G2; Mouse BD Fc Block) and further incubation with the following labeled mAb and appropriate isotype controls: biotin-labeled anti-BP-1 (6C3, eBioscience); fluorescein isothiocyanate (FITC)-labeled anti-CD4 (RM4-5, Tonbo Biosciences), anti-B220 (Ra3-6B2, Tonbo), anti-CD44 (IM7, BD Biosciences), and anti-CD24 (M1/69, BD Pharmingen); phycoerythrin-labeled anti-IgD (11-26, SouthernBiotech), anti-NK1.1 (PK136, BD Biosciences), anti-CD8 (53-6.7, BioLegend), anti-FoxP3 (3G3, Tonbo), anti-CD19 (1D3, Tonbo), and anti-ALCAM (eBioALC48, eBiosciences); PerCP-Cy5.5-labeled anti-CD3 (145-2 C11, Tonbo), anti-CD8 (53-6.7, Tonbo), anti-CD44 (IM7, Tonbo), and streptavidin (BD Biosciences); allophycocyanin-labeled anti-CD3 (145-2 C11, Tonbo), anti-CD62L (MEL-14, Tonbo), anti-CD3ε (145-2 C11, Tonbo), anti-IgM (II/41, eBioscience), anti-LAP (TW7-16B4, Biolegend), and anti-CD25 (PC61.5, eBiosciences); APC-Cy7-labeled anti-CD25 (PC61, BD Pharmingen); Pe-Cy7-labeled anti-CD5 (53–7.3, eBiosciences), anti-CD19 (1D3, Tonbo), and anti-CD4 (GK1.5, BioLegend); violetFluor 450-labeled anti-B220 (RA3-6B2, Tonbo) and anti-CD8 (53-6.7, Tonbo). .. FoxP3 intracellular staining was performed with the phycoerythrin-labeled anti-mouse/rat Treg Staining Kit (eBioscience), according to the manufacturer’s instructions.

    other:

    Article Title: NK-B cell cross talk induces CXCR5 expression on natural killer cells
    Article Snippet: Anti-IgD , Southern Biotech , 2030-07.



    Similar Products

    93
    Miltenyi Biotec igd antibody, anti-mouse
    Igd Antibody, Anti Mouse, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+igd/IgD+Antibody%2C+anti-mouse/custom%40130-102-410%4042575315
    Average 93 stars, based on 1 article reviews
    igd antibody, anti-mouse - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec igd
    Igd, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+igd/Erythroid+Cells+Antibody%2C+anti-rat%2C+REAfinity/bio_rxiv__64898__2026__04__18__719387-179-42-51
    Average 96 stars, based on 1 article reviews
    igd - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    93
    R&D Systems aggrecan
    Aggrecan, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+igd/Human+Aggrecan+G1-IGD-G2+Domains+Antibody/pm41996266-137-9-11
    Average 93 stars, based on 1 article reviews
    aggrecan - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec human recombinant anti igd viobrightr720
    Human Recombinant Anti Igd Viobrightr720, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+igd/IgD+Antibody%2C+anti-human%2C+REAfinity/pmc13328623-6-0-4
    Average 94 stars, based on 1 article reviews
    human recombinant anti igd viobrightr720 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    90
    Miltenyi Biotec anti human igd microbeads
    Anti Human Igd Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+igd/Anti-IgD+MicroBeads%2C+human/bio_rxiv__64898__2026__03__30__715354-313-9-16
    Average 90 stars, based on 1 article reviews
    anti human igd microbeads - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    93
    R&D Systems aggrecan fragments
    Effect of EFEMP1 knockdown by small interfering RNA (siRNA) on chondrocyte phenotype. A The human chondrocyte cell line C20A4 was transfected with either EFEMP1 siRNA (siEFEMP1) or scrambled siRNA (siCtrl). EFEMP1 and MMP-13 protein expression was analyzed by Western blotting. B Chondrocyte-related gene expression, <t>including</t> <t>SOX9,</t> <t>aggrecan</t> (ACAN), MMP13, type X collagen (COL10A1), and type II collagen (COL2A1), was assessed by quantitative PCR in siEFEMP1- and siCtrl-treated C20A4 cells. C Phosphokinase protein arrays were used to profile phosphorylation changes in intracellular proteins extracted from C20A4 chondrocytes. D Spot intensities exhibiting changes greater than ± 25% between groups were quantified using ImageJ software. Red lines indicate baseline levels from the siCtrl group. E Phosphorylation of p70S6K at threonine 421/serine 424 (T421/T424) was further examined by Western blot analysis. Data are presented as mean ± standard error of the mean (SEM). Statistical significance was determined using an independent-samples t-test. * P < 0.05, ** P < 0.01, and *** P < 0.001
    Aggrecan Fragments, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+igd/Human+Aggrecan+G1-IGD-G2+Domains+Antibody/pmc12999771-100-28-32
    Average 93 stars, based on 1 article reviews
    aggrecan fragments - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    SouthernBiotech igd fitc
    Effect of EFEMP1 knockdown by small interfering RNA (siRNA) on chondrocyte phenotype. A The human chondrocyte cell line C20A4 was transfected with either EFEMP1 siRNA (siEFEMP1) or scrambled siRNA (siCtrl). EFEMP1 and MMP-13 protein expression was analyzed by Western blotting. B Chondrocyte-related gene expression, <t>including</t> <t>SOX9,</t> <t>aggrecan</t> (ACAN), MMP13, type X collagen (COL10A1), and type II collagen (COL2A1), was assessed by quantitative PCR in siEFEMP1- and siCtrl-treated C20A4 cells. C Phosphokinase protein arrays were used to profile phosphorylation changes in intracellular proteins extracted from C20A4 chondrocytes. D Spot intensities exhibiting changes greater than ± 25% between groups were quantified using ImageJ software. Red lines indicate baseline levels from the siCtrl group. E Phosphorylation of p70S6K at threonine 421/serine 424 (T421/T424) was further examined by Western blot analysis. Data are presented as mean ± standard error of the mean (SEM). Statistical significance was determined using an independent-samples t-test. * P < 0.05, ** P < 0.01, and *** P < 0.001
    Igd Fitc, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+igd/Goat+Anti-Human+IgD-FITC/pm41820674-308-17-23
    Average 93 stars, based on 1 article reviews
    igd fitc - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    SouthernBiotech igd
    Effect of EFEMP1 knockdown by small interfering RNA (siRNA) on chondrocyte phenotype. A The human chondrocyte cell line C20A4 was transfected with either EFEMP1 siRNA (siEFEMP1) or scrambled siRNA (siCtrl). EFEMP1 and MMP-13 protein expression was analyzed by Western blotting. B Chondrocyte-related gene expression, <t>including</t> <t>SOX9,</t> <t>aggrecan</t> (ACAN), MMP13, type X collagen (COL10A1), and type II collagen (COL2A1), was assessed by quantitative PCR in siEFEMP1- and siCtrl-treated C20A4 cells. C Phosphokinase protein arrays were used to profile phosphorylation changes in intracellular proteins extracted from C20A4 chondrocytes. D Spot intensities exhibiting changes greater than ± 25% between groups were quantified using ImageJ software. Red lines indicate baseline levels from the siCtrl group. E Phosphorylation of p70S6K at threonine 421/serine 424 (T421/T424) was further examined by Western blot analysis. Data are presented as mean ± standard error of the mean (SEM). Statistical significance was determined using an independent-samples t-test. * P < 0.05, ** P < 0.01, and *** P < 0.001
    Igd, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+igd/Goat+Anti-Human+IgD-PE/bio_rxiv__64898__2026__03__04__709621-300-55-58
    Average 93 stars, based on 1 article reviews
    igd - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec igd hi b cells
    Effect of EFEMP1 knockdown by small interfering RNA (siRNA) on chondrocyte phenotype. A The human chondrocyte cell line C20A4 was transfected with either EFEMP1 siRNA (siEFEMP1) or scrambled siRNA (siCtrl). EFEMP1 and MMP-13 protein expression was analyzed by Western blotting. B Chondrocyte-related gene expression, <t>including</t> <t>SOX9,</t> <t>aggrecan</t> (ACAN), MMP13, type X collagen (COL10A1), and type II collagen (COL2A1), was assessed by quantitative PCR in siEFEMP1- and siCtrl-treated C20A4 cells. C Phosphokinase protein arrays were used to profile phosphorylation changes in intracellular proteins extracted from C20A4 chondrocytes. D Spot intensities exhibiting changes greater than ± 25% between groups were quantified using ImageJ software. Red lines indicate baseline levels from the siCtrl group. E Phosphorylation of p70S6K at threonine 421/serine 424 (T421/T424) was further examined by Western blot analysis. Data are presented as mean ± standard error of the mean (SEM). Statistical significance was determined using an independent-samples t-test. * P < 0.05, ** P < 0.01, and *** P < 0.001
    Igd Hi B Cells, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+igd/IgD+Antibody%2C+anti-mouse%2C+REAdye_lease/pmc12710606-220-15-20
    Average 95 stars, based on 1 article reviews
    igd hi b cells - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    Image Search Results


    Effect of EFEMP1 knockdown by small interfering RNA (siRNA) on chondrocyte phenotype. A The human chondrocyte cell line C20A4 was transfected with either EFEMP1 siRNA (siEFEMP1) or scrambled siRNA (siCtrl). EFEMP1 and MMP-13 protein expression was analyzed by Western blotting. B Chondrocyte-related gene expression, including SOX9, aggrecan (ACAN), MMP13, type X collagen (COL10A1), and type II collagen (COL2A1), was assessed by quantitative PCR in siEFEMP1- and siCtrl-treated C20A4 cells. C Phosphokinase protein arrays were used to profile phosphorylation changes in intracellular proteins extracted from C20A4 chondrocytes. D Spot intensities exhibiting changes greater than ± 25% between groups were quantified using ImageJ software. Red lines indicate baseline levels from the siCtrl group. E Phosphorylation of p70S6K at threonine 421/serine 424 (T421/T424) was further examined by Western blot analysis. Data are presented as mean ± standard error of the mean (SEM). Statistical significance was determined using an independent-samples t-test. * P < 0.05, ** P < 0.01, and *** P < 0.001

    Journal: Journal of Molecular Medicine (Berlin, Germany)

    Article Title: Targeting EFEMP1 enhances chondrogenesis and inhibits hypertrophic differentiation in a spontaneous osteoarthritis mouse model

    doi: 10.1007/s00109-026-02656-y

    Figure Lengend Snippet: Effect of EFEMP1 knockdown by small interfering RNA (siRNA) on chondrocyte phenotype. A The human chondrocyte cell line C20A4 was transfected with either EFEMP1 siRNA (siEFEMP1) or scrambled siRNA (siCtrl). EFEMP1 and MMP-13 protein expression was analyzed by Western blotting. B Chondrocyte-related gene expression, including SOX9, aggrecan (ACAN), MMP13, type X collagen (COL10A1), and type II collagen (COL2A1), was assessed by quantitative PCR in siEFEMP1- and siCtrl-treated C20A4 cells. C Phosphokinase protein arrays were used to profile phosphorylation changes in intracellular proteins extracted from C20A4 chondrocytes. D Spot intensities exhibiting changes greater than ± 25% between groups were quantified using ImageJ software. Red lines indicate baseline levels from the siCtrl group. E Phosphorylation of p70S6K at threonine 421/serine 424 (T421/T424) was further examined by Western blot analysis. Data are presented as mean ± standard error of the mean (SEM). Statistical significance was determined using an independent-samples t-test. * P < 0.05, ** P < 0.01, and *** P < 0.001

    Article Snippet: Samples were incubated overnight at 4 °C with primary antibodies against EFEMP1 (1:100, NBP1-77040; NOVUS, USA), SOX9 (1:50, sc-166505; Santa Cruz Biotechnology, USA), MMP-13 (1:100, GTX100665; GeneTex, USA), aggrecan fragments (1:100, AF1220; R&D Systems, USA), COL2A1 (1:100, ab34712; Abcam, UK), and COL10A1 (1:100, GTX37732; GeneTex, USA).

    Techniques: Knockdown, Small Interfering RNA, Transfection, Expressing, Western Blot, Gene Expression, Real-time Polymerase Chain Reaction, Phospho-proteomics, Software

    Immunofluorescence analysis of cartilage markers following EFEMP1 antibody treatment in STR/ort mice. A Representative immunofluorescence (IF) staining for EFEMP1, SOX9, MMP13, aggrecan fragments, COL2A1, and COL10A1 in the medial femoral condyle (MF) and medial tibial plateau (MT). Nuclei were counterstained with DAPI (blue), and articular cartilage regions are outlined by orange dashed lines. B Quantification of fluorescence intensity in articular cartilage regions of the femoral condyle and tibial plateau, with medial and lateral compartments combined. EFEMP1 and SOX9 signals were normalized to DAPI, whereas MMP13, aggrecan fragments, COL10A1, and COL2A1 signals were quantified as absolute FITC intensity. Data are presented as mean ± standard error of the mean (SEM). Statistical analysis was performed using an independent-samples t -test. P < 0.05, P < 0.01, and ** P < 0.001

    Journal: Journal of Molecular Medicine (Berlin, Germany)

    Article Title: Targeting EFEMP1 enhances chondrogenesis and inhibits hypertrophic differentiation in a spontaneous osteoarthritis mouse model

    doi: 10.1007/s00109-026-02656-y

    Figure Lengend Snippet: Immunofluorescence analysis of cartilage markers following EFEMP1 antibody treatment in STR/ort mice. A Representative immunofluorescence (IF) staining for EFEMP1, SOX9, MMP13, aggrecan fragments, COL2A1, and COL10A1 in the medial femoral condyle (MF) and medial tibial plateau (MT). Nuclei were counterstained with DAPI (blue), and articular cartilage regions are outlined by orange dashed lines. B Quantification of fluorescence intensity in articular cartilage regions of the femoral condyle and tibial plateau, with medial and lateral compartments combined. EFEMP1 and SOX9 signals were normalized to DAPI, whereas MMP13, aggrecan fragments, COL10A1, and COL2A1 signals were quantified as absolute FITC intensity. Data are presented as mean ± standard error of the mean (SEM). Statistical analysis was performed using an independent-samples t -test. P < 0.05, P < 0.01, and ** P < 0.001

    Article Snippet: Samples were incubated overnight at 4 °C with primary antibodies against EFEMP1 (1:100, NBP1-77040; NOVUS, USA), SOX9 (1:50, sc-166505; Santa Cruz Biotechnology, USA), MMP-13 (1:100, GTX100665; GeneTex, USA), aggrecan fragments (1:100, AF1220; R&D Systems, USA), COL2A1 (1:100, ab34712; Abcam, UK), and COL10A1 (1:100, GTX37732; GeneTex, USA).

    Techniques: Immunofluorescence, Staining, Fluorescence